Rinvoq

Upadacitinib · UPADACITINIB 30 mg/1 · Tablet, Extended Release · Oral · AbbVie Inc.

NDC 00074-2310-20 · 14 TABLET, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Matched to CMS's representative package for this drug (NDC 00074-2310-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$227.48per unit

middle half $223.22–$232.71 · 5,402 plans · Apr 1, 2026

Est. net of rebatesⓘ

$136.49–$170.61

brand drug — est. 25-40% rebate off the price at left

Coverage & restrictions

98%of plans cover it

tier 5 · prior auth 98% · step therapy 0% · qty limit 94%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for upadacitinib (oral solid) in the next 90 days

sole-source market · price up 5% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $7,146.56 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA211675
TE code: —
Approval date: Aug 16, 2019
Patents / exclusivity: 75 patents, 14 exclusivities

Type	Number / code	Expires
exclusivity	ODE-538	Apr 28, 2032
exclusivity	ODE-481	Apr 26, 2031
exclusivity	ODE-481	Apr 26, 2031
exclusivity	ODE-481	Apr 26, 2031
exclusivity	I-966	Apr 28, 2028
exclusivity	I-946	Apr 26, 2027
exclusivity	NPP	Apr 26, 2027
exclusivity	NPP	Apr 26, 2027
exclusivity	I-946	Apr 26, 2027
exclusivity	I-946	Apr 26, 2027
exclusivity	NPP	Apr 26, 2027
exclusivity	I-919	May 18, 2026

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Upadacitinib (Tablet, Extended Release)

Labeler	Strength	First seen	Last seen
AbbVie Inc.	UPADACITINIB 15 mg/1	Jul 15, 2026	Sep 2, 2026
AbbVie Inc.	UPADACITINIB 45 mg/1	Jul 15, 2026	Sep 2, 2026
AbbVie Inc.	UPADACITINIB 30 mg/1	Jul 15, 2026	Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rinvoq — NDC 00074-2310-20," retrieved September 3, 2026, https://drugdashboards.com/drug/00074231020.

Free to cite with attribution — see how the data is put together.